Ahn, M. J., Chiu, C. H., Cheng, Y., Han, J. Y., Goldberg, S. B., Greystoke, A., … Mok, T. (2018). Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29, ix151–ix152. https://doi.org/10.1093/annonc/mdy425.003

Ahn, M. J., C. H. Chiu, Y. Cheng, J. Y. Han, S. B. Goldberg, A. Greystoke, J. Crawford, et al. “Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 29 (November 1, 2018): ix151–52. https://doi.org/10.1093/annonc/mdy425.003.

Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29:ix151–2.

Ahn, M. J., et al. “Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 29, Nov. 2018, pp. ix151–52. Scopus, doi:10.1093/annonc/mdy425.003.

Ahn MJ, Chiu CH, Cheng Y, Han JY, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok T. Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29:ix151–ix152.